Terns Surges 29.6% in Three Months: Will the Momentum Continue?

Shares of Terns Pharmaceuticals, Inc. (TERN) , a clinical-stage biopharmaceutical company, rose 29.6% in the past three months compared with the industry's growth of 7.4%. The stock outperformed the sector and the S&P 500 Index during the said time frame. The outperformance can be attributed to encouraging pipeline progress of its obesity and oncology candidates. TERN Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Terns Targets Lucrative Obesity Market Terns is developing a p ...